RADNOR, Pennsylvania, September 2, 2025 - Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company listed on Nasdaq as MLYS, has initiated an underwritten public offering of $175.0 million worth of shares of its common stock. The company specializes in developing medications for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other conditions linked to dysregulated aldosterone. Additionally, Mineralys plans to allow the underwriters a 30-day option to acquire up to an extra $26.25 million of its common stock at the public offering price, excluding underwriting discounts and commissions. All securities in this offering will be from Mineralys. The completion of the offering, as well as the final size and terms, are subject to market conditions and other variables, with no guarantee of certainty on timing.